EBITDA for Bristol-Myers Squibb (BMY)
According to Bristol-Myers Squibb's latest reported financial statements, the company's current EBITDA (TTM) is $14.54B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$14.54B
YoY change
+359.1%
5Y CAGR
+24.2%
Peak year (2021)
$20.12B
Cumulative EBITDA
$232.34B
EBITDA history chart for Bristol-Myers Squibb (BMY) from 1987 to 2025
EBITDA history table for Bristol-Myers Squibb (BMY) from 1987 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $14.54B | +359.1% | ||
| 2024 | $3.17B | -83.6% | ||
| 2023 | $19.37B | +0.8% | ||
| 2022 | $19.22B | -4.5% | ||
| 2021 | $20.12B | +308.2% | ||
| 2020 | $4.93B | -33.2% | ||
| 2019 | $7.38B | +8.7% | ||
| 2018 | $6.79B | +11.0% | ||
| 2017 | $6.12B | -5.4% | ||
| 2016 | $6.46B | +145.1% | ||
| 2015 | $2.64B | -13.6% | ||
| 2014 | $3.05B | -20.8% | ||
| 2013 | $3.85B | +20.3% | ||
| 2012 | $3.20B | -58.7% | ||
| 2011 | $7.75B | +13.6% | ||
| 2010 | $6.82B | +5.1% | ||
| 2009 | $6.49B | +10.0% | ||
| 2008 | $5.90B | +33.5% | ||
| 2007 | $4.42B | +33.4% | ||
| 2006 | $3.31B | -29.0% | ||
| 2005 | $4.67B | -13.2% | ||
| 2004 | $5.37B | -6.1% | ||
| 2003 | $5.72B | +18.3% | ||
| 2002 | $4.84B | -17.8% | ||
| 2001 | $5.89B | -12.6% | ||
| 2000 | $6.73B | +13.8% | ||
| 1999 | $5.92B | +16.5% | ||
| 1998 | $5.08B | +1.0% | ||
| 1997 | $5.03B | +12.5% | ||
| 1996 | $4.47B | +10.1% | ||
| 1995 | $4.06B | +14.5% | ||
| 1994 | $3.55B | +30.9% | ||
| 1993 | $2.71B | +20.2% | ||
| 1992 | $2.25B | -25.1% | ||
| 1991 | $3.01B | +14.4% | ||
| 1990 | $2.63B | +105.9% | ||
| 1989 | $1.28B | -34.6% | ||
| 1988 | $1.96B | +20.1% | ||
| 1987 | $1.63B | — |
EBITDA values are taken from Bristol-Myers Squibb's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Bristol-Myers Squibb (BMY) most recent annual EBITDA stands at $14.54B (2025) – surged 359.1% year-over-year.
Bristol-Myers Squibb EBITDA has recorded the values shown across consecutive periods, with a +24.2% compound annual growth rate over 2020–2025 (5 years).
Between 2021 and 2025, Bristol-Myers Squibb EBITDA declined 27.7%, falling from $20.12B to $14.54B.
The highest annual EBITDA of $20.12B was reported in 2021. The lowest in the available history was $1.28B in 1989.
Bristol-Myers Squibb (BMY) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $24.21B.
Bristol-Myers Squibb EBITDA by Year
Bristol-Myers Squibb EBITDA 2025: $14.54B
Bristol-Myers Squibb EBITDA in 2025 was $14.54B, surged 359.1% from 2024.
Bristol-Myers Squibb EBITDA 2024: $3.17B
Bristol-Myers Squibb EBITDA in 2024 was $3.17B, plunged 83.6% below 2023.
Bristol-Myers Squibb EBITDA 2023: $19.37B
Bristol-Myers Squibb EBITDA in 2023 was $19.37B, edged up 0.8% from 2022.
Bristol-Myers Squibb EBITDA 2022: $19.22B
Bristol-Myers Squibb EBITDA in 2022 was $19.22B, edged down 4.5% below 2021.
Bristol-Myers Squibb EBITDA 2021: $20.12B
Bristol-Myers Squibb EBITDA in 2021 was $20.12B.
See more financial history for Bristol-Myers Squibb (BMY).
Sector peers — EBITDA
Companies in the same sector as Bristol-Myers Squibb, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Bristol-Myers Squibb's EBITDA?
- Latest reported EBITDA for Bristol-Myers Squibb (BMY) is $14.54B (period ending December 31, 2025).
How has Bristol-Myers Squibb EBITDA changed year-over-year?
- Bristol-Myers Squibb (BMY) EBITDA changed +359.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Bristol-Myers Squibb EBITDA?
- Bristol-Myers Squibb (BMY) EBITDA compound annual growth rate is +24.2% over the most recent 5 years available.
When did Bristol-Myers Squibb EBITDA hit its highest annual value?
- Bristol-Myers Squibb EBITDA reached its highest annual value of $20.12B in 2021.
What was Bristol-Myers Squibb EBITDA in 2024?
- Bristol-Myers Squibb (BMY) EBITDA in 2024 was $3.17B.
What was Bristol-Myers Squibb EBITDA in 2025?
- Bristol-Myers Squibb (BMY) EBITDA in 2025 was $14.54B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
BMY Overview
Company profile, financial tools, and key metrics
BMY Revenue Counter
Earns $1,528 every second. See per minute, hour, and day.
BMY Earnings Counter
Earns $223.65 per second net profit. See per minute, hour, and day.
BMY Economic Scale
Exceeds Bahrain's GDP. Compare with world economies.
BMY What If Invested
What if you had invested $1,000? See historical returns from any date.
BMY How It Makes Money
Discover visual breakdown of $48.19B in revenue — where it comes from and where it goes.
BMY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BMY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BMY Daily Price Character
Steady · 47.3% historical win rate (green days). Streaks & record days.
BMY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BMY Stock Split History
6 splits on record. Dates, ratios, and cumulative multiple.
BMY Dividend Profile
Yield: 4.34%. Safety: 7/8. See full history.
BMY Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
BMY Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.